EGFR and non-small cell lung carcinoma: The agent was approved in September 2019 in China as first line treatment for EGFR mutated NSCLC.50 It remains to be investigated whether anlotinib added to a third-generation EGFR-TKI would confer similar or greater benefit on EGFR-mutated, advanced NSCLC patients.